CDIO

Healthcare Biotechnology

Cardio Diagnostics Holdings, Inc.

$2.00

-0.08 -3.85% today

Price History

Not enough data

Key Stats

Market Cap

5.92M

Avg Volume

55,307

EPS

-$2.80

52W High

$7.91

52W Low

$0.97

Div. Yield

0.0%

Valuation

Forward P/E

-8.00

P/B Ratio

0.80

P/S Ratio

409.62

EV/EBITDA

-0.14

EV/Revenue

60.87

Margins

Gross Margin 100.0%

Operating Margin (27950.5%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Revenue Growth (YoY)

(28.3%)

Return on Equity

(75.4%)

Return on Assets

(44.1%)

Liquidity & Leverage

Current Ratio

17.15

Quick Ratio

15.56

Debt / Equity

0.05

Total Cash

5.59M

Total Debt

369,698

About

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

cdio.ai